Alteplase (also: recombinant tissue-plasminogen activator; ALT) is currently the most commonly used and guideline-recommended thrombolytic agent for patients with AIS within 4.5 h after stroke onset [10]. The gene discussed is GPT; the disease is androgen insensitivity syndrome.